The novel diagnostic protein panel in our study included CA125, a specific marker for ovarian cancer, and its performance in diagnosing ovarian cancer including their early-stage disease and discriminating between benign and malignant ovarian tumors in the population was more effective than CA125. The gene discussed is MUC16; the disease is ovarian carcinoma.